Clinical trial
Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study
NCT07886801 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy of Molecularly Driven, Time-limited Treatment With Ropeg-interferon in Newly Diagnosed Patients With JAK2- Mutant Polycythemia Vera - a Multicenter, Single-arm, Phase II Study
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 30, 2026
- Completion date
- October 31, 2029
- Enrollment
- 55 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
jak2 mutation, polycythemia vera (pv)
Arms
As registered; 1 arm.
-
Ropeg-Interferon in People With Polycythemia Vera
Each patient will receive ropeg-IFN subcutaneously.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of patients who meet criteria for treatment discontinuation
and sustain the same criteria without treatment re-initiation at month 48
Lead sponsor's other trials
Memorial Sloan Kettering Cancer Center, most recent start first.
+1,958 more trials See the organization page
Similar trials
Same condition (Polycythemia Vera) and phase, most recent start first.
+86 more trials See the condition page